含钌配合物的脂质纳米载体：癌症治疗的潜在途径。
Lipid based nanovectors containing ruthenium complexes: a potential route in cancer therapy.
作者信息
Vaccaro Mauro, Del Litto Raffaella, Mangiapia Gaetano, Carnerup Anna M, D'Errico Gerardino, Ruffo Francesco, Paduano Luigi
机构信息
Department of Chemistry, Università degli Studi di Napoli "Federico II", Via Cinthia, Naples, Italy.
出版信息
Chem Commun (Camb). 2009 Mar 21(11):1404-6. doi: 10.1039/b820368g. Epub 2009 Jan 21.
DOI:10.1039/b820368g
PMID:19259602
Abstract
Ruthenium complexes offer new perspectives in cancer therapy; towards this aim we have synthesized a new amphiphilic unimer able to coordinate ruthenium complexes and to form liposomes.
摘要
钌配合物为癌症治疗提供了新的视角；为了实现这一目标，我们合成了一种新型两亲性单分子，它能够配位钌配合物并形成脂质体。
相似文献
1
Lipid based nanovectors containing ruthenium complexes: a potential route in cancer therapy.含钌配合物的脂质纳米载体：癌症治疗的潜在途径。
Chem Commun (Camb). 2009 Mar 21(11):1404-6. doi: 10.1039/b820368g. Epub 2009 Jan 21.
2
Ruthenium-based complex nanocarriers for cancer therapy.基于钌的复杂纳米载体用于癌症治疗。
Biomaterials. 2012 May;33(14):3770-82. doi: 10.1016/j.biomaterials.2012.01.057. Epub 2012 Feb 21.
3
Arene ruthenium complexes as anticancer agents.钌芳配合物作为抗癌剂。
Dalton Trans. 2010 Feb 21;39(7):1673-88. doi: 10.1039/b916860p. Epub 2009 Oct 23.
4
Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes.有机金属化学、生物学与医学：钌芳烃抗癌配合物
Chem Commun (Camb). 2005 Oct 14(38):4764-76. doi: 10.1039/b508531b. Epub 2005 Aug 26.
5
Ruthenium(II)-arene complexes with strong fluorescence: insight into the underlying mechanism.具有强荧光的钌（II）-芳烃配合物：对潜在机制的洞察
Chemistry. 2012 Jul 9;18(28):8617-21. doi: 10.1002/chem.201200960. Epub 2012 Jun 14.
6
A novel ruthenium(II) arene based intercalator with potent anticancer activity.一种具有强大抗癌活性的新型钌（II）芳烃基嵌入剂。
Dalton Trans. 2009 Jul 14(26):5071-3. doi: 10.1039/b907296a. Epub 2009 May 12.
7
Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.抗水解的有机金属钌-芳烃抗癌药物的研发。
Inorg Chem. 2006 Oct 30;45(22):9006-13. doi: 10.1021/ic061008y.
8
In silico evolution of substrate selectivity: comparison of organometallic ruthenium complexes with the anticancer drug cisplatin.底物选择性的计算机模拟进化：有机金属钌配合物与抗癌药物顺铂的比较
Chem Commun (Camb). 2006 Jun 21(23):2451-3. doi: 10.1039/b601590e. Epub 2006 May 5.
9
Anticancer cationic ruthenium nanovectors: from rational molecular design to cellular uptake and bioactivity.抗癌阳离子钌纳米载体：从合理的分子设计到细胞摄取和生物活性。
Biomacromolecules. 2013 Aug 12;14(8):2549-60. doi: 10.1021/bm400104b. Epub 2013 Jun 27.
10
Arene control over thiolate to sulfinate oxidation in albumin by organometallic ruthenium anticancer complexes.有机金属钌抗癌配合物对白蛋白中硫醇盐至亚磺酸盐氧化的芳烃控制。
Chemistry. 2009 Jul 6;15(27):6586-94. doi: 10.1002/chem.200900699.
引用本文的文献
1
Safety and Efficacy Evaluation In Vivo of a Cationic Nucleolipid Nanosystem for the Nanodelivery of a Ruthenium(III) Complex with Superior Anticancer Bioactivity.用于具有优异抗癌生物活性的钌（III）配合物纳米递送的阳离子核脂质纳米系统的体内安全性和有效性评估
Cancers (Basel). 2021 Oct 14;13(20):5164. doi: 10.3390/cancers13205164.
2
Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems.乳腺癌化疗选择：多靶点钌（III）配合物载入核脂质纳米系统的临床前验证概述。
Cells. 2020 Jun 5;9(6):1412. doi: 10.3390/cells9061412.
3
Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity.抗癌钌（III）配合物及含钌（III）纳米制剂：作用机制与生物活性的最新进展
Pharmaceuticals (Basel). 2019 Sep 26;12(4):146. doi: 10.3390/ph12040146.
Zotero 插件